1. Modulation of the acute phase response and in vitro measurement of interleukin-1 activity following administration of dexamethasone to adjuvant-arthritic rats.
- Author
-
Connolly KM, Stecher VJ, LaBrie T, and Fluno C
- Subjects
- Animals, Arthritis, Experimental immunology, C-Reactive Protein analysis, Iron blood, Male, Phospholipases A antagonists & inhibitors, Rats, Rats, Inbred Lew, Serum Albumin analysis, Arthritis drug therapy, Arthritis, Experimental drug therapy, Dexamethasone pharmacology, Interleukin-1 analysis
- Abstract
Adjuvant-arthritic (AA) rats were medicated with dexamethasone to determine if this glucocorticoid suppressed the activity of interleukin-1 (IL-1) or the acute phase response. Dexamethasone (0.1 mg/kg, p.o.) administered daily for two weeks to AA rats, significantly (p less than or equal to 0.01) decreased high splenic IL-1 production (60% inhibition). Dexamethasone at a 0.5 mg/kg dose reduced AA rat splenic IL-1 production below normal (100% inhibition). In addition, dexamethasone significantly inhibited the AA rat acute phase response as measured by reduction of plasma C-reactive protein levels and enhancement of plasma albumin and iron levels. Following medication with 0.02, 0.1 or 0.5 mg/kg dexamethasone, high plasma C-reactive protein levels decreased by 33, 77 and 95% respectively, compared to untreated AA controls. Under the same dosing regimen of 0.02, 0.1 or 0.5 mg/kg dexamethasone, plasma albumin levels increased by 44, 128 and 239% respectively, while plasma iron levels rose by 19, 64 and 98% respectively, compared to AA controls. At the 0.02, 0.1 and 0.5 mg/kg doses dexamethasone also significantly reduced injected and noninjected paw swelling in AA rats. In view of the ability of dexamethasone to decrease IL-1 production and the acute phase response often associated with it, it is possible that part of the anti-inflammatory activity of dexamethasone may stem from inhibition of IL-1 formation in vivo.
- Published
- 1988
- Full Text
- View/download PDF